| Literature DB >> 35233709 |
Parisa Sedaghati1, Maryam Goudarzian2, Somayeh Ahmadabadi3, Seyed Mojtaba Tabatabai-Asl4.
Abstract
PURPOSE: Good posture plays a significant role for the elderly in achieving optimal quality of life. This study aimed to evaluate the impact of multicomponent functional training with postural correction on functional balance in the elderly with a history of falling.Entities:
Keywords: Aging; Fall; Intervention; Physical activity
Year: 2022 PMID: 35233709 PMCID: PMC8888785 DOI: 10.1186/s40634-022-00459-x
Source DB: PubMed Journal: J Exp Orthop ISSN: 2197-1153
Fig. 1Diagram of randomized control trial
CONSORT 2010 checklist of information to include when reporting a randomize trial
| Section/Topic | Item No | Checklist item | Reported on page No |
|---|---|---|---|
|
| |||
| 1a | Identification as a randomised trial in the title | N/Y | |
| 1b | Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) | 1 | |
|
| |||
| Background and objectives | 2a | Scientific background and explanation of rationale | 1–3 |
| 2b | Specific objectives or hypotheses | 3 | |
|
| |||
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio | 4 |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons | 4 | |
| Participants | 4a | Eligibility criteria for participants | 4 |
| 4b | Settings and locations where the data were collected | 3–4 | |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered | 5–6 |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed | 6 |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | N/Y | |
| Sample size | 7a | How sample size was determined | 5 |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | N/Y | |
| Randomisation: | |||
| Sequence generation | 8a | Method used to generate the random allocation sequence | 5 |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size) | N/Y | |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned | 5 |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions | 5 |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how | N/Y |
| 11b | If relevant, description of the similarity of interventions | N/Y | |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes | 7 |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses | 7 | |
|
| |||
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome | 7 |
| 13b | For each group, losses and exclusions after randomisation, together with reasons | 7 | |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up | 7–8 |
| 14b | Why the trial ended or was stopped | N/Y | |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group | 7–8 |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups | 7–8 |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval) | 7–8 |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | N/Y | |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory | N/Y |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) | N/Y |
|
| |||
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses | 10 |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings | 8 |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence | 8–10 |
|
| 9–10 | ||
| Registration | 23 | Registration number and name of trial registry | 12 |
| Protocol | 24 | Where the full trial protocol can be accessed, if available | 6 |
| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders | 12 |
MCFT Program for the 8 weeks and progression of the complexity of secondary tasks [4, 33]
| Phases program | First month | Second month |
|---|---|---|
| Type of physical activity | Strength Static balance + dual-task + corrective posturea | Strength + Dynamic balance + dual-task + corrective posturea |
| 1-Warm-up 5 min | Range of motion for different joints | |
| 2-Strength lower extremity: Chair squat and stand, Leg flexion, Leg extension, Leg abduction, Hip extension, Standing on the tips of toes and heels | 4–5 ex: 2 sets, 8 rep | 4–5 ex:1–2 sets, 12 rep |
| 3-Balance: Feet-together stance, legged stand, Semi-tandem/Tandem balance, Circuit training, Gait training-stairs & obstacle function | 2–3 ex, progressive difficulty in sitting position and progressing to standing position | 4–5 ex, progressive difficulty in standing position with decreasing arm support and increasing instability with foam mat |
| 4- Dual-task (cognitive function): One type of cognitive exercise in each session) Naming colors/days of the week/names, Counting by twos starting 0 till a number ≤ 30, Counting backward by ones( | In 2–3 of strength ex and 1–2 of balance ex | In 1–2 of strength ex and 3–4 of balance ex |
| 5-Cool down 5 min | Stretching, breathing exercises | |
ex exercises, rep repetitions
aParticipants must maintain correct posture during all types of physical activity
Anthropometric measurements
Outcome Variable
Tests to assess the functional abilities
| Test | Parameters | Description |
|---|---|---|
| Berg balance test | Postural stability | Performance of 14 functional tasks [ |
| Timed Up and Go (with and without D-T) | Functional balance | Get up from a chair, walk 3 m at a normal pace, turn around, walk back to the chair and sit down again [ |
| Short Physical Performance Battery | Lower extremity function: static balance, gait speed, and getting in and out of a chair | Side-by-side, semi-tandem, and tandem stands (10 s); 4 m walk test at a comfortable speed and 5 quickly sit to stand from a chair without upper extremity assistance [ |
| tandem gait test(TGT) | Dynamic gait balance | to take 12 consecutive steps with the feet aligned heel to toe in tandem on a straight line with their eyes open (stopwatch), without walking aids, and with their arms hanging by the sides of their body [ |
Comparing the demographic data of the participants between the experimental and control groups
| Group | EG ( | CG ( |
|
|---|---|---|---|
| Age (y) | 70.42 ± 2.70 | 71.07 ± 2.26 | NS |
| Height (cm) | 168.42 ± 2.40 | 167.35 ± 2.23 | NS |
| Weight (kg) | 67.12 ± 5.19 | 66.05 ± 2.37 | NS |
| BMI | 23.68 ± 1.21 | 23.59 ± 1.11 | NS |
| MMSE (score) | 26.08 ± 1.25 | 26.33 ± 1.37 | NS |
| Fall number | 2.62 ± 0.50 | 2.69 ± 0.48 | NS |
EG Experimental Group, CG Control Group, NS non-significant, MMSE Mini-Mental State Examination
The Pre and Post Test Means of Experimental and Control Groups (n = 28)
| Groups | E G ( | C G( | ||||||
|---|---|---|---|---|---|---|---|---|
|
|
|
|
|
|
|
|
| |
|
| 27.00 ± 2.18 | 31.00 ± 3.13 | -7.95 | 0.001a | 26.00 ± 1.79 | 25.64 ± 1.90 | 0.92 | 0.373 |
|
| 15.11 ± 1.36 | 13.87 ± 1.64 | 5.54 | 0.001a | 14.86 ± 1.60 | 15.05 ± 1.60 | -1.24 | 0.236 |
|
| 16.33 ± 1.47 | 15.39 ± 1.67 | 5.94 | 0.001a | 16.32 ± 1.60 | 16.37 ± 1.62 | -0.61 | 0.548 |
|
| 6.35 ± 1.00 | 8.00 ± 1.24 | -8.25 | 0.001a | 6.14 ± 1.23 | 6.50 ± 1.09 | -0.36 | 0.720 |
|
| 6.42 ± 0.85 | 8.21 ± 1.25 | -8.33 | 0.001a | 6.28 ± 1.20 | 6.35 ± 1.15 | -1.58 | 0.136 |
EG Experimental Group, CG Control Group, PreT Pre Test, PostT Post Test, BBS Berg Balance Scale, TUG Timed Up and Go test, TG tandem gait, SPPB Short Physical Performance Battery test, aStatistically significant
Analysis of Covariance for the Selected Variables among Experimental Group & Control Groups (n = 28)
| Variables | Type III Sum of Squares | F | Sig | Partial Eta Squared |
|---|---|---|---|---|
| BBS | 87.87 | 35.08 | 0.001a | 0.626 |
| TUG(s) | 3.38 | 6.62 | 0.018 | 0.240 |
| TUG-Dual(s) | 1.69 | 8.09 | 0.01a | 0.278 |
| TG | 8.11 | 12.69 | 0.002a | 0.377 |
| SPPB | 7.62 | 14.72 | 0.001a | 0.412 |
BBS Berg Balance Scale, TUG Timed Up and Go test, TG tandem gait, SPPB Short Physical Performance Battery test, aStatistically significant.